Sanofi announced the closing of the sale of a 50% controlling stake of Opella to U.S. private equity firm Clayton, Dubilier & Rice (CD&R), enabling the launch of Opella is as a standalone consumer health care company.
Sanofi remains a significant shareholder, retaining a 48.2% stake in Opella. Sanofi and CD&R had entered into exclusive negotiations for the potential sale of the controlling stake back in October 2024. Sanofi has now received total net cash proceeds of around $11.4 billion (€10 billion) from the deal.
France-based Opella is the third-largest global player in the over-the-counter and vitamins, minerals and supplements space. It produces over 100 brands at 13 global manufacturing sites. Opella's portfolio includes well-known brands such as Allegra, Doliprane and Dulcolax.